Mackenzie Ian R A, Neumann Manuela
Department of Pathology, University of British Columbia and Vancouver General Hospital, Vancouver, Canada.
Department of Neuropathology, University of Tübingen and German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
J Neurochem. 2016 Aug;138 Suppl 1:54-70. doi: 10.1111/jnc.13588. Epub 2016 Jun 15.
Frontotemporal dementia (FTD) is a clinical syndrome with a heterogeneous molecular basis. The past decade has seen the discovery of several new FTD-causing genetic mutations and the identification of many of the relevant pathological proteins. The current neuropathological classification is based on the predominant protein abnormality and allows most cases of FTD to be placed into one of three broad molecular subgroups; frontotemporal lobar degeneration with tau, TDP-43 or FET protein accumulation. This review will describe our current understanding of the molecular basis of FTD, focusing on insights gained from the study of human postmortem tissue, as well as some of the current controversies. Most cases of FTD can be subclassified into one of three broad molecular subgroups based on the predominant protein that accumulates as pathological cellular inclusions. Understanding the associated pathogenic mechanisms and recognizing these FTD molecular subtypes in vivo will likely be crucial for the development and use of targeted therapies. This article is part of the Frontotemporal Dementia special issue.
额颞叶痴呆(FTD)是一种具有异质性分子基础的临床综合征。在过去十年中,发现了几种新的导致FTD的基因突变,并鉴定出了许多相关的病理蛋白。当前的神经病理学分类基于主要的蛋白异常情况,使得大多数FTD病例能够被归入三个主要分子亚组之一;即伴有tau蛋白、TDP - 43或FET蛋白聚集的额颞叶变性。本综述将描述我们目前对FTD分子基础的理解,重点关注从人类尸检组织研究中获得的见解以及当前的一些争议。基于作为病理性细胞内含物积累的主要蛋白,大多数FTD病例可被细分为三个主要分子亚组之一。了解相关的致病机制并在体内识别这些FTD分子亚型对于靶向治疗的开发和应用可能至关重要。本文是《额颞叶痴呆》特刊的一部分。